1. Home
  2. ALT vs MYN Comparison

ALT vs MYN Comparison

Compare ALT & MYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • MYN
  • Stock Information
  • Founded
  • ALT 1997
  • MYN 1992
  • Country
  • ALT United States
  • MYN United States
  • Employees
  • ALT N/A
  • MYN N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • MYN Finance Companies
  • Sector
  • ALT Health Care
  • MYN Finance
  • Exchange
  • ALT Nasdaq
  • MYN Nasdaq
  • Market Cap
  • ALT 292.0M
  • MYN 358.2M
  • IPO Year
  • ALT N/A
  • MYN N/A
  • Fundamental
  • Price
  • ALT $3.83
  • MYN $9.31
  • Analyst Decision
  • ALT Strong Buy
  • MYN
  • Analyst Count
  • ALT 6
  • MYN 0
  • Target Price
  • ALT $17.40
  • MYN N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • MYN 86.0K
  • Earning Date
  • ALT 08-12-2025
  • MYN 01-01-0001
  • Dividend Yield
  • ALT N/A
  • MYN 4.12%
  • EPS Growth
  • ALT N/A
  • MYN N/A
  • EPS
  • ALT N/A
  • MYN N/A
  • Revenue
  • ALT $20,000.00
  • MYN N/A
  • Revenue This Year
  • ALT N/A
  • MYN N/A
  • Revenue Next Year
  • ALT $761,880.20
  • MYN N/A
  • P/E Ratio
  • ALT N/A
  • MYN N/A
  • Revenue Growth
  • ALT N/A
  • MYN N/A
  • 52 Week Low
  • ALT $2.90
  • MYN $8.47
  • 52 Week High
  • ALT $11.16
  • MYN $10.62
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • MYN 48.18
  • Support Level
  • ALT $3.35
  • MYN $9.20
  • Resistance Level
  • ALT $3.66
  • MYN $9.33
  • Average True Range (ATR)
  • ALT 0.19
  • MYN 0.07
  • MACD
  • ALT 0.07
  • MYN -0.01
  • Stochastic Oscillator
  • ALT 86.18
  • MYN 50.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock

Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.

Share on Social Networks: